This trial is conducted in Europe. The aim of this trial is to test for bioequivalence of two formulations of liraglutide.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
22
Single dose administered as subcutaneous injection
Single dose administered as subcutaneous injection
Novo Nordisk Investigational Site
Neu-Ulm, Germany
Area under the Curve (AUC) (0-t)
Cmax, maximum concentration
AUC (0-infinity)
tmax, time to maximum concentration
t½, terminal half-life
Terminal elimination rate constant
Adverse events
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.